223 related articles for article (PubMed ID: 31117178)
41. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
Zibert A; Hüsing-Kabar A; Schmidt H
Dtsch Med Wochenschr; 2019 Oct; 144(20):1438-1443. PubMed ID: 31594020
[TBL] [Abstract][Full Text] [Related]
42. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
Gonzalez-Duarte A
Clin Auton Res; 2019 Apr; 29(2):245-251. PubMed ID: 29511897
[TBL] [Abstract][Full Text] [Related]
43. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
44. Patisiran: First Global Approval.
Hoy SM
Drugs; 2018 Oct; 78(15):1625-1631. PubMed ID: 30251172
[TBL] [Abstract][Full Text] [Related]
45. Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy.
Pinto MV; Dyck PJB; Gove LE; McCauley BM; Ackermann EJ; Hughes SG; Waddington-Cruz M; Dyck PJ
J Neurol Sci; 2018 Nov; 394():78-83. PubMed ID: 30219500
[TBL] [Abstract][Full Text] [Related]
46. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
[TBL] [Abstract][Full Text] [Related]
47. A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment.
Severi D; Palumbo G; Spina E; Iovino A; Nolano M; Manganelli F; Tozza S
Neurol Sci; 2023 Apr; 44(4):1419-1422. PubMed ID: 36576645
[TBL] [Abstract][Full Text] [Related]
48. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.
Lavigne-Moreira C; Marques VD; Gonçalves MVM; de Oliveira MF; Tomaselli PJ; Nunez JC; do Nascimento OJM; Barreira AA; Marques W
J Peripher Nerv Syst; 2018 Jun; 23(2):134-137. PubMed ID: 29520877
[TBL] [Abstract][Full Text] [Related]
49. Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
Hayashi Y; Jono H
Biol Pharm Bull; 2018; 41(12):1737-1744. PubMed ID: 30504675
[TBL] [Abstract][Full Text] [Related]
50. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies.
Vita G; Vita GL; Stancanelli C; Gentile L; Russo M; Mazzeo A
Neurol Sci; 2019 Apr; 40(4):661-669. PubMed ID: 30847674
[TBL] [Abstract][Full Text] [Related]
51. Neuropathy Associated with Systemic Amyloidosis.
Kaku M; Berk JL
Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
[TBL] [Abstract][Full Text] [Related]
52. Lumbar Spinal Stenosis: A Rare Presentation of Hereditary Transthyretin Amyloidosis.
Çakar A; Atmaca MM; Kotan D; Durmuş H; Deymeer F; Oflazer P; Parman Y
Noro Psikiyatr Ars; 2022; 59(1):77-79. PubMed ID: 35317495
[TBL] [Abstract][Full Text] [Related]
53. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Buxbaum JN
Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
[TBL] [Abstract][Full Text] [Related]
54. [What gnaws at the heart and gets on the nerves].
Kristen AV
Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
[TBL] [Abstract][Full Text] [Related]
55. Patisiran for the treatment of patients with familial amyloid polyneuropathy.
Rizk M; Tüzmen S
Drugs Today (Barc); 2019 May; 55(5):315-327. PubMed ID: 31131842
[TBL] [Abstract][Full Text] [Related]
56. Early-Onset of Transthyretin Amyloidosis in a Young Afro-Caribbean Woman With Thr60Ala Mutation.
Keppel SC; Brannagan TH; Helmke S; Santos JL; Gonzalez LJ; Fayerman R; Teruya S; Maurer MS
JACC Case Rep; 2020 Nov; 2(13):2063-2067. PubMed ID: 34317109
[TBL] [Abstract][Full Text] [Related]
57. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
[TBL] [Abstract][Full Text] [Related]
58. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.
Gendre T; Planté-Bordeneuve V
Clin Auton Res; 2019 Sep; 29(Suppl 1):25-31. PubMed ID: 31506870
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
[TBL] [Abstract][Full Text] [Related]
60. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
Coelho T; Maurer MS; Suhr OB
Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
